Phase 2Active, not recruiting
Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)
- Sponsor
- Vanderbilt University Medical Center (Academic or other)
- Enrolment
- 100 planned
- Conditions
- Asthma
- Interventions
- Semaglutide Pen Injector 2.4mg weekly; Placebo
- Ages
- adults, older adults
- Registry
- NCT05254314
From the registry
This is a randomized placebo-controlled trial of semaglutide, an FDA-approved therapy for the treatment of type 2 diabetes mellitus and obesity, in adults with symptomatic asthma despite the use of inhaled steroids and with excess body weight. This study will test the central hypothesis that semaglutide will improve asthma control and reduce airway inflammation due to direct effects on the respiratory tract in adult asthma associated with obesity.
Primary outcomes
- The efficacy of semaglutide on asthma control questionnaire-7 score in subjects with symptoms, persistent asthma and obesity.
- The impact of semaglutide once weekly on serum periostin in subjects with symptomatic, persistent asthma and obesity.